{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:39:03Z","timestamp":1771231143431,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1124210"],"award-info":[{"award-number":["GNT1124210"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41391-020-0220-8","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T20:03:03Z","timestamp":1583179383000},"page":"527-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-1479","authenticated-orcid":false,"given":"Kerri","family":"Beckmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Adolfsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Kennedy","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"220_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441\u201350.","journal-title":"Circulation"},{"key":"220_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0405-5","volume":"13","author":"T Lloyd","year":"2015","unstructured":"Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010. BMC Med. 2015;13:171.","journal-title":"BMC Med"},{"key":"220_CR3","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1002\/cncr.31549","volume":"124","author":"S Negoita","year":"2018","unstructured":"Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801\u201314.","journal-title":"Cancer"},{"key":"220_CR4","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"220_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S2213-8587(15)00377-0","volume":"4","author":"MJ Brown","year":"2016","unstructured":"Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"220_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"220_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10:23\u201329.","journal-title":"Heart Fail Rev"},{"key":"220_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl J Med. 1999;341:709\u201317.","journal-title":"N. Engl J Med"},{"key":"220_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1210\/endo-97-1-52","volume":"97","author":"P Corvol","year":"1975","unstructured":"Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 1975;97:52\u201358.","journal-title":"Endocrinology"},{"key":"220_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-018-0318-7","volume":"18","author":"L Cao","year":"2018","unstructured":"Cao L, Zhang S, Jia CM, He W, Wu LT, Li YQ, et al. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies. BMC Urol. 2018;18:17.","journal-title":"BMC Urol"},{"key":"220_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10552-008-9280-0","volume":"20","author":"C Rodriguez","year":"2009","unstructured":"Rodriguez C, Jacobs EJ, Deka A, Patel AV, Bain EB, Thun MJ, et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2009;20:671\u20139.","journal-title":"Cancer Causes Control"},{"key":"220_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/21681805.2018.1559882","volume":"52","author":"A Siltari","year":"2018","unstructured":"Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scand J Urol. 2018;52:321\u20137.","journal-title":"Scand J Urol"},{"key":"220_CR13","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10552-011-9819-3","volume":"22","author":"KJ Kemppainen","year":"2011","unstructured":"Kemppainen KJ, Tammela TL, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study. Cancer Causes Control. 2011;22:1445\u201352.","journal-title":"Cancer Causes Control"},{"key":"220_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/HJH.0000000000001130","volume":"35","author":"YW Chuang","year":"2017","unstructured":"Chuang YW, Yu MC, Huang ST, Yang CK, Chen CH, Lo YC, et al. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study. J Hypertens. 2017;35:170\u20137.","journal-title":"J Hypertens"},{"key":"220_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bcp.13152","volume":"83","author":"IS Mackenzie","year":"2017","unstructured":"Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharm. 2017;83:653\u201363.","journal-title":"Br J Clin Pharm"},{"key":"220_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ajh\/hpw030","volume":"29","author":"GC Roush","year":"2016","unstructured":"Roush GC, Sica DA. Diuretics for hypertension: a review and update. Am J Hypertens. 2016;29:1130\u20137.","journal-title":"Am J Hypertens"},{"key":"220_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/ije\/dys068","volume":"42","author":"M Van Hemelrijck","year":"2013","unstructured":"Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42:956\u201367.","journal-title":"Int J Epidemiol"},{"key":"220_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3109\/0284186X.2014.939299","volume":"54","author":"K Tomic","year":"2015","unstructured":"Tomic K, Berglund A, Robinson D, Hjalm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54:158\u201363.","journal-title":"Acta Oncol"},{"key":"220_CR19","unstructured":"Nationellt v\u00e5rdprogram f\u00f6r prostatacancer Cis. 2019. http:\/\/www.cancercentrum.se\/samverkan\/cancerdiagnoser\/prostata\/vardprogram\/gallande-vardprogram-prostatacancer\/. Viewed Dec 2019."},{"key":"220_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"220_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep31358","volume":"6","author":"Z Liang","year":"2016","unstructured":"Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.","journal-title":"Sci Rep"},{"key":"220_CR22","first-page":"328","volume":"8","author":"D Rathnayake","year":"2010","unstructured":"Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010;8:328\u201332.","journal-title":"Skinmed"},{"key":"220_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"SM Sirmans","year":"2013","unstructured":"Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1\u201313.","journal-title":"Clin Epidemiol"},{"key":"220_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MOU.0000000000000464","volume":"28","author":"MA Liss","year":"2018","unstructured":"Liss MA, Thompson IM. Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Curr Opin Urol. 2018;28:42\u201345.","journal-title":"Curr Opin Urol"},{"key":"220_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276\u2013308.","journal-title":"Endocr Rev"},{"key":"220_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839\u201345.","journal-title":"Hypertension"},{"key":"220_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820\u20135.","journal-title":"Am J Cardiol"},{"key":"220_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","volume":"74","author":"B Dhondt","year":"2019","unstructured":"Dhondt B, Buelens S, Van Besien J, Beysens M, De Bleser E, Ost P et al. Abiraterone and spironolactone in prostate cancer: a combination to avoid. Acta Clin Belg. 2019;74:439\u201344.","journal-title":"Acta Clin Belg"},{"key":"220_CR29","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.clgc.2016.08.006","volume":"15","author":"T Flynn","year":"2017","unstructured":"Flynn T, Guancial EA, Kilari M, Kilari D. Case report: spironolactone withdrawal associated with a dramatic response in a patient with metastatic castrate-resistant prostate cancer. Clin Genitourin Cancer. 2017;15:e95\u2013e97.","journal-title":"Clin Genitourin Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0220-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0220-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0220-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:51Z","timestamp":1684618491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-0220-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1038\/s41391-020-0220-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}